Approval of 4 in 1 anti-HIV drugs

On August 27, the US Food and Drug Administration (FDA) approved a new anti-HIV drug combining four drugs to fight AIDS-causing viruses.

The drug called Stribild , also known as 4 in 1 anti-HIV drug, was produced by Gilead Sciences Inc., approved once a day to control HIV virus in adults who have never been treated for infection. relate to.

4 in 1 anti-HIV pill integrated by 4 antagonists
help fight HIV effectively (Photo: Huffingtonpost.com)

The ingredients include the previously approved emtricitabine antiviral drugs and tenofovir disoproxil fumarate and are now sold under the name Truvada. There are also 2 new drugs: elvitegravir and cobicistat. Elvitegravir will work to intervene in one of the enzymes that the HIV virus needs to multiply. And Cobicistat helps prolong the effectiveness of elvitegravir.

Research shows that 88 to 90% of patients taking Stribild have low levels of HIV virus that cannot be detected in the blood after 48 weeks. Meanwhile, this rate in patients taking Atripla (an anti-HIV drug containing Truvada and another drug) is 87%.

However, Stribild also has side effects such as severe liver damage, lactic acid accumulation, nausea and diarrhea.

Earlier, in early 2012, Gilead's Truvada drug was also approved by FDA to become the first preventive medicine for healthy people in high-risk groups.